IP Library Patent Application 14386519
Patent Application
App. No. 14/386,519

Cell Suspension and Use Thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/386,519
Abstract

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

Claims (42)

1 . A cell suspension for use in an epithelium-related procedure, comprising:

a population of cells including viable and functioning cells derived from an epithelial tissue sample;

wherein the population of cells, prior to being used in an epithelium-related procedure, are exposed to a condition selected from the group consisting of stress and an exogenous agent;

wherein the population of cells, when used in said epithelium-related procedure and applied to a recipient site, promote treatment, healing, reconstructing, resurfacing, repigmentation and/or regeneration of epithelial tissues.

2 . The cell suspension of claim 1 , wherein the viable and functioning cells include differentiated cells and cells capable of dividing or differentiating.

3 . The cell suspension of claim 1 , wherein the epithelial tissue sample is obtained from one or more of skin epithelium, respiratory epithelium, vascular epithelium, corneal epithelium, and glandular epithelium.

4 . The cell suspension of claim 1 , wherein when the epithelial tissue sample is skin tissue sample, the viable cells are derived from a dermal layer, epidermal layer, or both a dermal and an epidermal layer of the skin tissue sample.

5 . The cell suspension of claim 1 , wherein when the epithelial tissue sample is skin tissue sample, the population of cells comprises keratinocytes, melanocytes, fibroblasts, Langerhans cells, or any combination of the foregoing.

6 . The cell suspension of claim 1 , wherein when the epithelial tissue sample is skin tissue sample, the population of cells comprises skin stem cells.

7 . The cell suspension of claim 6 , wherein the skin stem cells are combined with non-stem cells.

8 . The cell suspension of claim 1 , wherein said stress is one or more of hypoxia, heat, mechanical trauma, nutrient deprivation, and enzyme exposure.

9 . The cell suspension of claim 1 , wherein the population of cells exhibit a stress-induced characteristic.

10 . The cell suspension of claim 9 , wherein the stress-induced characteristic is an elevated level of expression of a protein selected from the group consisting of Hsp90 and Hsp90α.

11 . The cell suspension of claim 1 , further comprising said exogenous agent.

12 . The cell suspension of claim 11 , wherein the exogenous agent is a heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, a growth factor, adipose stem cells, or any combination of the foregoing.

13 . The cell suspension of claim 1 , wherein when the epithelial tissue sample is skin tissue sample, the epithelium-related procedure comprises skin wound treatment, skin tissue graft, skin aesthetic procedure, or dermal treatment.

14 . The cell suspension of claim 13 , wherein the skin wound is acute wound, artificially created wound, or chronic wound.

15 . The cell suspension of claim 1 , wherein the population of cells are seeded to a matrix or scaffold in vitro or in situ at a recipient site, for use in said epithelium-related procedure.

16 . A method for preparing cells for use in an epithelium-related procedure, comprising:

providing a population of cells including viable and functioning cells derived from an epithelial tissue sample; and

exposing the population of cells to a condition selected from the group consisting of stress and an exogenous agent.

17 - 22 . (canceled)

23 . The method of claim 16 , wherein said stress is one or more of hypoxia, heat, mechanical trauma, nutrient deprivation, and enzyme exposure.

24 . The method of claim 16 , wherein said stress induces the population of cells to exhibit a stress-induced characteristic.

25 . The method of claim 24 , wherein the stress-induced characteristic is an elevated level of expression of a protein selected from the group consisting of Hsp90 and Hsp90α.

26 . The method of claim 24 , wherein said stress induces expression of a heat shock protein by the population of cells, thereby obtaining cells for use in said epithelium-related procedure that have an elevated level of said heat shock protein compared to a control level of said heat shock protein without being exposed to said stress.

27 . The method of claim 26 , wherein the heat shock protein is selected from the group consisting of Hsp90 and Hsp90α.

28 . The method of claim 16 , wherein the exogenous agent is a heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, a growth factor, adipose stem cells, or any combination of the foregoing.

29 - 32 . (canceled)

33 . A method for preparing and using cells in an epithelium-related procedure, comprising:

applying, to a recipient site on a patient in need thereof, a population of cells including viable and functioning cells derived from an epithelial tissue sample; and

providing to the population of cells a condition selected from the group consisting of stress and an exogenous agent to promote epithelial treatment, healing, reconstructing, resurfacing, repigmentation and/or regeneration in said patient.

34 - 39 . (canceled)

40 . The method of claim 33 , wherein said stress is one or more of hypoxia, heat, mechanical trauma, nutrient deprivation, and enzyme exposure.

41 . The method of claim 33 , wherein said stress induces the population of cells to exhibit a stress-induced characteristic.

42 . The method of claim 41 , wherein the stress-induced characteristic is an elevated level of expression of a protein selected from the group consisting of Hsp90 and Hsp90α.

43 . The method of claim 41 , wherein said stress induces expression of a heat shock protein by the population of cells, thereby obtaining cells for use in said epithelium-related procedure that have an elevated level of said heat shock protein compared to a control level of said heat shock protein without being exposed to said stress.

44 . The method of claim 43 , wherein the heat shock protein is selected from the group consisting of Hsp90 and Hsp90α.

45 . The method of claim 33 , wherein the exogenous agent is a heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, a growth factor, adipose stem cells, or any combination of the foregoing.

46 - 47 . (canceled)

48 . The method of claim 33 , further comprising applying the population of cells to a recipient site.

49 . The method of claim 33 , further comprising seeding the population of cells to a matrix or scaffold in vitro or in situ at a recipient site.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2026
From: ORCO IV LLC
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 073473/0540 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2024
From: ORCO IV LLC
To: AVITA MEDICAL PTY LIMITED
Reel/Frame 066960/0046 →
SECURITY INTEREST Recorded Apr 1, 2024
From: AVITA MEDICAL AMERICAS, LLC
To: ORCO IV LLC
Reel/Frame 066960/0144 →
SECURITY INTEREST Recorded Dec 13, 2023
From: AVITA MEDICAL PTY LIMITED
To: ORCO IV LLC
Reel/Frame 065856/0614 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 035881 FRAME: 0357. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 30, 2018
From: QUICK, ANDREW; DOLPHIN, WILLIAM
To: AVITA MEDICAL LTD
Reel/Frame 047689/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2018
From: QUICK, ANDREW; DOLPHIN, WILLIAM
To: AVITA MEDICAL LTD
Reel/Frame 047692/0916 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: QUICK, ANDREW; DOLPHIN, WILLIAM
To: AVITA MEDICAL LTD.
Reel/Frame 035881/0357 →